Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Vor Biopharma Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 SC 13D/A RA CAPITAL MANAGEMENT, L.P. reports a 33.7% stake in VOR BIOPHARMA INC.
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform"
05/26/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/14/2023 ARS Form ARS - Annual Report to Security Holders:
04/14/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/14/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2023 8-K Quarterly results
03/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/14/2023 SC 13G/A Paradigm Biocapital Advisors LP reports a 9.9% stake in Vor Biopharma Inc.
01/10/2023 SC 13G/A FMR LLC reports a 12.1% stake in VOR BIOPHARMA INC
12/21/2022 EFFECT Form EFFECT - Notice of Effectiveness:
12/14/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
12/14/2022 8-K Termination of a Material Definitive Agreement  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/09/2022 SC 13D/A RA CAPITAL MANAGEMENT, L.P. reports a 34.8% stake in VOR BIOPHARMA INC.
12/08/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/07/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among Vor Biopharma Inc. and Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein",
"Opinion of Cooley LLP",
"Securities Purchase Agreement, by and between Vor Biopharma Inc. and RA Capital Healthcare Fund, L.P",
"Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million"
12/07/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel and Tolerated Mylotarg TM",
"Company Presentation"
11/29/2022 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/14/2022 SC 13D/A RA CAPITAL MANAGEMENT, L.P. reports a 28.8% stake in VOR BIOPHARMA INC.
10/27/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/17/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/28/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/21/2022 EFFECT Form EFFECT - Notice of Effectiveness:
03/14/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/14/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/09/2022 SC 13G/A FMR LLC reports a 8.5% stake in VOR BIOPHARMA INC
11/10/2021 10-Q Quarterly Report for the period ended September 30, 2021
08/09/2021 10-Q Quarterly Report for the period ended June 30, 2021
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy